Frail older adults with type 2 diabetes who switched from insulin injections to IDegLira (insulin degludec/liraglutide combination) gained significant lean mass, reduced fat mass, and improved insulin resistance while needing less total insulin over 6 months.
Body cell mass +7.82 kg/m in 6 monthsFrail elderly patients (mean age 80) gained significant lean mass and lost fat after switching to insulin/liraglutide combination from standard insulin
What the researchers found
In 36 frail insulin-treated older adults (mean age 79.6) switched to IDegLira for 6 months:
Insulin reduction:
- Total insulin dropped from 34.52 to 24.30 U/day
- Bolus insulin nearly discontinued
- IDegLira titrated from 15.66 to 22.41 units/day
Body composition improvements (adjusted for covariates):
- Fat-free mass: +3.17 kg/m
- Body cell mass: +7.82 kg/m
- Phase angle: +1.75° (cellular health marker)
- Basal metabolic rate: +217.6 kcal
- Fat mass: decreased significantly (P < 0.001)
Metabolic improvements:
- HbA1c: 7.29% → 7.05% (P = 0.089, favorable trend)
- Insulin resistance (METS-IR): 42.39 → 32.84 (P < 0.0001)
Why it matters
Frailty in the elderly is characterized by muscle loss (sarcopenia), and traditional insulin therapy can worsen this by promoting fat gain and reducing muscle mass. This study shows that adding liraglutide (via the IDegLira combination) reverses this pattern — patients gained muscle and lost fat. For the growing population of frail elderly diabetic patients, this represents a potentially transformative change in treatment approach. The simpler once-daily injection also reduces treatment burden for patients who may struggle with complex insulin regimens.
How the study worked
Retrospective analysis of 36 frail insulin-treated older adults (18 women, 18 men, mean age 79.6 years) from the STOP (Simplifying Treatment in Older People) study. Patients were switched from existing insulin regimens to once-daily IDegLira. Body composition was measured by bioelectrical impedance analysis (BIA) at baseline and 6 months. Changes were evaluated using adjusted mixed models for repeated measures controlling for multiple covariates. Glycemic control (HbA1c) and insulin resistance (METS-IR index) were also tracked.
What this study cannot tell us
Retrospective design without a control group limits causal conclusions. Small sample (36 patients) at a single center. Bioelectrical impedance analysis (BIA) is less precise than DXA or MRI for body composition. The body composition improvements could partially reflect reduced fluid retention from lower insulin doses rather than true muscle gain. Only 6-month follow-up — longer-term effects are unknown. The HbA1c change was not statistically significant (P = 0.089).
How to read the evidence
This is a retrospective, single-arm analysis from a named study (STOP) without a control group. While the body composition and metabolic changes are impressive and statistically significant after covariate adjustment, the lack of randomization and blinding means confounders could influence results.
When this study was published
Published in 2025 in European Geriatric Medicine, this is a very current study addressing the growing clinical challenge of managing diabetes in an aging population.
The bigger picture
As populations age and diabetes prevalence grows, managing diabetes in frail elderly patients is becoming a major clinical challenge. The concern about sarcopenic obesity — losing muscle while gaining fat — is central to geriatric medicine. This study suggests GLP-1 receptor agonists (via IDegLira) can shift body composition favorably even in the most vulnerable patients. Combined with the GLP-1RA's cardiovascular and potential neuroprotective benefits, this positions the liraglutide component as particularly valuable in older adults.
Questions still open
- Would IDegLira show similar body composition benefits in a larger randomized controlled trial against continuing insulin therapy?
- How much of the body composition improvement is from liraglutide versus reduced insulin dosing?
- Do these body composition improvements translate to reduced falls, improved mobility, and longer independence in frail elderly patients?
Common questions
What is IDegLira and why is it useful for elderly patients?
Why is losing fat and gaining muscle so important for frail elderly patients?
Read the original research
Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.
European geriatric medicine
Citation
Mancinetti, Francesca; Xenos, Dionysios; De Fano, Michelantonio; Mazzieri, Alessio; Ercolani, Sara; Mecocci, Patrizia; Porcellati, Francesca; Boccardi, Virginia. (2025). Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.. European geriatric medicine. https://doi.org/10.1007/s41999-025-01271-3